EXPRESSION OF CONCERN: Rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-γ (PPAR-γ), reduce ischaemia/reperfusion injury of the gut

IF 6.8 2区医学 Q1 PHARMACOLOGY & PHARMACY British Journal of Pharmacology Pub Date : 2024-12-02 DOI:10.1111/bph.17421

{"title":"EXPRESSION OF CONCERN: Rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-γ (PPAR-γ), reduce ischaemia/reperfusion injury of the gut","authors":"","doi":"10.1111/bph.17421","DOIUrl":null,"url":null,"abstract":"EXPRESSION OF CONCERN: \n S. Cuzzocrea, B. Pisano, L. Dugo, A. Ianaro, N. S. A. Patel, R. Di Paola, T. Genovese, P. K. Chatterjee, M. Di Rosa, A. P. Caputi, and C. Thiemermann, “ Rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-γ (PPAR-γ), reduce ischaemia/reperfusion injury of the gut,” British Journal of Pharmacology 140, no. 2 (2003): 366–376, https://doi.org/10.1038/sj.bjp.0705419.This expression of concern is for the above article, published online on 2 February 2009 in Wiley Online Library (wileyonlinelibrary.com), and has been issued by agreement between the journal Editor-in-Chief, Péter Ferdinandy; the British Pharmacological Society; and John Wiley & Sons Ltd. The expression of concern has been agreed due to third-party concerns related to the data presented in the article. Indicators for cloned image elements and inappropriate undeclared image modification were found in multiple image parts and several panels in Figures 1, 9, and 11. Due to the significant time elapsed since publication, the authors were unable to provide the original images. Therefore, the journal has decided to issue an Expression of Concern to inform and alert the readers.","PeriodicalId":9262,"journal":{"name":"British Journal of Pharmacology","volume":"182 3","pages":"925"},"PeriodicalIF":6.8000,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bph.17421","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bph.17421","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

EXPRESSION OF CONCERN: S. Cuzzocrea, B. Pisano, L. Dugo, A. Ianaro, N. S. A. Patel, R. Di Paola, T. Genovese, P. K. Chatterjee, M. Di Rosa, A. P. Caputi, and C. Thiemermann, “ Rosiglitazone and 15-deoxy-Δ^12,14-prostaglandin J₂, ligands of the peroxisome proliferator-activated receptor-γ (PPAR-γ), reduce ischaemia/reperfusion injury of the gut,” British Journal of Pharmacology 140, no. 2 (2003): 366–376, https://doi.org/10.1038/sj.bjp.0705419.

This expression of concern is for the above article, published online on 2 February 2009 in Wiley Online Library (wileyonlinelibrary.com), and has been issued by agreement between the journal Editor-in-Chief, Péter Ferdinandy; the British Pharmacological Society; and John Wiley & Sons Ltd. The expression of concern has been agreed due to third-party concerns related to the data presented in the article. Indicators for cloned image elements and inappropriate undeclared image modification were found in multiple image parts and several panels in Figures 1, 9, and 11. Due to the significant time elapsed since publication, the authors were unable to provide the original images. Therefore, the journal has decided to issue an Expression of Concern to inform and alert the readers.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

关注表达：罗格列酮和15-deoxy-Δ12,14-前列腺素J2，过氧化物酶体增殖物激活受体-γ (PPAR-γ)的配体，减少肠道缺血/再灌注损伤。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

British Journal of Pharmacology 医学-药学

CiteScore

15.40

自引率

12.30%

发文量

270

审稿时长

2.0 months

期刊介绍： The British Journal of Pharmacology (BJP) is a biomedical science journal offering comprehensive international coverage of experimental and translational pharmacology. It publishes original research, authoritative reviews, mini reviews, systematic reviews, meta-analyses, databases, letters to the Editor, and commentaries. Review articles, databases, systematic reviews, and meta-analyses are typically commissioned, but unsolicited contributions are also considered, either as standalone papers or part of themed issues. In addition to basic science research, BJP features translational pharmacology research, including proof-of-concept and early mechanistic studies in humans. While it generally does not publish first-in-man phase I studies or phase IIb, III, or IV studies, exceptions may be made under certain circumstances, particularly if results are combined with preclinical studies.